Christopher R. Flowers, MD, MS, and colleagues shed light on recent updates in the treatment armamentarium for follicular lymphoma and highlight ongoing investigations of novel agents and combinations.
Current and Emerging Therapeutic Advances in Follicular Lymphoma
Matthew Lunning, DO, FACP, discusses considerations for community oncologists who treat patients with relapsed/refractory follicular lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
2
FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer
3
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
4
Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC
5